

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



QINGHAI BIOTECH PHARMACEUTICAL GROUP LIMITED

青海生物製藥集團有限公司

*(Formerly known as “Kaisa Health Group Holdings Limited 佳兆業健康集團控股有限公司”)
(incorporated in Bermuda with limited liability)*

(Stock Code: 876)

CHANGE OF COMPANY NAME, STOCK SHORT NAME, COMPANY WEBSITE AND COMPANY LOGOS

References are made to (i) the announcement (the “**Announcement**”) of Qinghai Biotech Pharmaceutical Group Limited (formerly known as Kaisa Health Group Holdings Limited) (the “**Company**”) dated 6 August 2026 relating to the Revised Proposed Change of Company Name, (ii) the circular of the Company dated 13 August 2026 (the “**Circular**”) and (iii) the announcement of the Company dated 1 September 2026 in relation to the poll results of the special general meeting (the “**SGM**”) of the Company held on 1 September 2026 regarding, among other things, the Revised Proposed Change of Company Name. Capitalised terms used herein shall have the same meanings as those defined in the Announcement and the Circular unless the context requires otherwise.

CHANGE OF COMPANY NAME

The Board is pleased to announce that subsequent to the approval of the Change of Company Name by the Shareholders at the SGM, the name of the Company has been changed from “Kaisa Health Group Holdings Limited” to “Qinghai Biotech Pharmaceutical Group Limited”, and “青海生物製藥集團有限公司” has been adopted as the secondary name of the Company in Chinese in place of the previous Chinese name “佳兆業健康集團控股有限公司”, both with effect from 3 September 2026 pursuant to the Certificate of Change of Name and the Certificate of Secondary Name issued by the Registrar of Companies in Bermuda on 3 September 2026. The Certificate of Registration of Alteration of Name of Registered Non-Hong Kong Company was issued by the Companies Registry in Hong Kong on 18 September 2026, confirming the registration of the Company’s new English and Chinese names in Hong Kong under Part 16 of the Companies Ordinance (Cap. 622 of the Laws of Hong Kong) (the “**Change of Company Name**”).

CHANGE OF STOCK SHORT NAME

Following the Change of Company Name, the stock short name of the Shares for trading on the Hong Kong Stock Exchange will be changed from “KAISA HEALTH” to “QH BIO PHARMA” in English and from “佳兆業健康” to “青海生物製藥” in Chinese with effect from 9:00 a.m. on 28 September 2026. The stock code of the Company on the Hong Kong Stock Exchange remains unchanged as “876”.

CHANGE OF COMPANY WEBSITE

The Board further announces that the Company’s website will be changed from “<http://www.kaisahealth.com>” to “<https://www.qhpharma.com>” with effect from the date of this announcement.

CHANGE OF COMPANY LOGO

The following logo which is also shown on the top of this announcement will be adopted as the logo of the Company to reflect the Change of Company Name with effect from the date of this announcement:



EFFECT OF THE CHANGE OF COMPANY NAME AND THE CHANGE OF COMPANY LOGO

The Change of Company Name and the change of the company logo will not affect any rights of the Shareholders or the Group’s daily business operation and its financial position.

All existing certificates of securities in issue bearing the former name of the Company and the former company logo will continue to be *prima facie* evidence of legal title to such securities and the existing share certificates will continue to be valid for trading, settlement, registration and delivery purposes. There will not be any arrangement for exchange of the existing share certificates for new share certificates bearing the new name and the new logo of the Company. Going forward, new share certificates of the Company bearing the logo as shown on the top of this announcement will be issued in the new name of the Company.

By Order of the Board
Qinghai Biotech Pharmaceutical Group Limited
Kwok Ying Shing
Chairman and Executive Director

Hong Kong, 23 September 2026

As at the date of this announcement, the Board comprises six executive Directors, namely Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun, Ms. Luo Tingting, Mr. Xie Binhong, Mr. Yang Feng and Mr. Ye Haoda and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying.